The immunomodulatory quinoline-3-carboxamide paquinimod reverses established fibrosis in a novel mouse model for liver fibrosis

Nina Fransén Pettersson, Adnan Deronic, Julia Nilsson, Tine Hannibal, Lisbeth Hansen, Anja Schmidt-Christensen, Fredrik Ivars, Dan Holmberg

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review

10 Citeringar (SciVal)

Sammanfattning

Quinoline-3-carboxamides (Q substances) are small molecule compounds with anti-inflammatory properties. In this study, we used one of these substances, Paquinimod, to treat a novel model for chronic liver inflammation and liver fibrosis, the NOD-Inflammation Fibrosis (N-IF) mouse. We show that treatment of N-IF mice significantly reduced inflammation and resulted in the regression of fibrosis, even when the treatment was initiated after onset of disease. The reduced disease phenotype was associated with a systemic decrease in the number and reduced activation of disease-promoting transgenic natural killer T (NKT)-II cells and their type 2-cytokine expression profile. Paquinimod treatment also led to a reduction of CD115+ Ly6Chi monocytes and CD11b+ F4/80+ CD206+ macrophages.
Originalspråkengelska
Artikelnummere0203228
TidskriftPLoS ONE
Volym13
Utgåva9
DOI
StatusPublished - 2018 sep 5

Ämnesklassifikation (UKÄ)

  • Immunologi inom det medicinska området

Fingeravtryck

Utforska forskningsämnen för ”The immunomodulatory quinoline-3-carboxamide paquinimod reverses established fibrosis in a novel mouse model for liver fibrosis”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här